{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:57Z","timestamp":1793214657201,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ophtha.2017.12.002","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T05:11:37Z","timestamp":1516425097000},"page":"850-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-5251","authenticated-orcid":false,"given":"Giovanni","family":"Staurenghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-7028","authenticated-orcid":false,"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Hykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.ophtha.2017.12.002_bib1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.5301\/EJO.2010.6050","article-title":"General pathophysiology of macular edema","volume":"21","author":"Scholl","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0039-6257(04)00109-2","article-title":"Macular edema","volume":"49","author":"Tranos","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.2174\/1381612821666150909095645","article-title":"Controversies in pharmacological treatment of inflammatory component of macular edema","volume":"21","author":"Vujosevic","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ophtha.2017.12.002_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jfo.2011.02.019","article-title":"[Epidemiologic study of pediatric uveitis: a series of 49 cases]","volume":"35","author":"Chebil","year":"2012","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2008.07.024","article-title":"Etiology and treatment of macular edema","volume":"147","author":"Johnson","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/09273948.2011.603878","article-title":"Intermediate uveitis in a pediatric Italian population","volume":"19","author":"Paroli","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2017.12.002_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IAE.0b013e31818a1fbc","article-title":"Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema","volume":"29","author":"Barone","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.68.11.815","article-title":"Long-term follow-up of central serous chorioretinopathy","volume":"68","author":"Gilbert","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00417-010-1366-1","article-title":"Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab","volume":"248","author":"He","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ajo.2005.03.049","article-title":"The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema","volume":"140","author":"van Kooij","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1023\/A:1002135518856","article-title":"Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids","volume":"97","author":"Wolfensberger","year":"1999","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease","volume":"54","author":"Gunther","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/14712598.2012.660523","article-title":"Ranibizumab for age-related macular degeneration","volume":"12","author":"Dhoot","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ophtha.2017.12.002_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ophtha.2010.04.016","article-title":"Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ophtha.2013.02.019","article-title":"Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study","volume":"120","author":"Lang","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL Study","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","article-title":"Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","article-title":"Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER","volume":"123","author":"Tadayoni","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ajo.2009.03.028","article-title":"Ranibizumab for refractory uveitis-related macular edema","volume":"148","author":"Acharya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/IAE.0b013e318213da43","article-title":"Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema","volume":"31","author":"Acharya","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jcrs.2007.07.046","article-title":"Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group","volume":"33","author":"Arevalo","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ophtha.2009.04.006","article-title":"Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results","volume":"116","author":"Arevalo","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/jop.2009.0089","article-title":"Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa","volume":"25","author":"Artunay","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0b013e3181e378af","article-title":"Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema","volume":"31","author":"Bae","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/08820538.2013.847110","article-title":"The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy","volume":"30","author":"Bakri","year":"2015","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2006.11.028","article-title":"Intravitreal bevacizumab for treatment of uveitic macular edema","volume":"114","author":"Cordero Coma","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/cxo.12125","article-title":"Cytokine levels of the aqueous humour in central serous chorioretinopathy","volume":"97","author":"Jung","year":"2014","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.ophtha.2017.12.002_bib34","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1111\/j.1755-3768.2009.01835.x","article-title":"Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy","volume":"89","author":"Lee","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/jop.2011.0045","article-title":"The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab","volume":"27","author":"Lee","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/eye.2008.388","article-title":"Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab","volume":"23","author":"Weiss","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.12.002_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00006982-198808030-00001","article-title":"Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation","volume":"8","author":"Bradford","year":"1988","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archopht.1974.03900060257001","article-title":"Experience with nontreatment of central serous choroidopathy","volume":"91","author":"Klein","year":"1974","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3928\/23258160-20160324-03","article-title":"OCT angiography findings in acute central serous chorioretinopathy","volume":"47","author":"Feucht","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bjophthalmol-2016-309247","article-title":"Preferred practice pattern in central serous chorioretinopathy","volume":"101","author":"Mehta","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib41","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1097\/IAE.0000000000000621","article-title":"Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy","volume":"35","author":"Shiode","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib42","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/IAE.0b013e3181d8e7fe","article-title":"Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy","volume":"30","author":"Lim","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib43","article-title":"Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: 12-month results of the MINERVA study","author":"Lai","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib44","article-title":"Summary of product characteristics. Lucentis 10 mg\/ml solution for injection","author":"European Medicines Agency","year":"2016","journal-title":"Novartis"},{"key":"10.1016\/j.ophtha.2017.12.002_bib45","first-page":"30","article-title":"Combination of intravitreal bevacizumab and peripheral photocoagulation: an alternative treatment in Eales disease","volume":"2","author":"Cp","year":"2013","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00417-015-3233-6","article-title":"Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease","volume":"254","author":"Park","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3928\/23258160-20160419-07","article-title":"Treatment of Coats' disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-Tenon corticosteroids","volume":"47","author":"Sein","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2017.12.002_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5\u00a0mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Prunte","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.002_bib49","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017323436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017323436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T20:43:45Z","timestamp":1666557825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017323436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0161642017323436"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.002","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license ?(<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/?creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}